It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1 ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...